Clinical Trial Update: A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]

View source ↗

Summary

This report covers results from a Phase II repeat-dose study of losmapimod in patients with focal segmental glomerulosclerosis to assess its effects on proteinu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Glomerulosclerosis, Focal Segmental | Phase 2 | Status: COMPLETED | Results posted: 2017-06-12